Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-05-09
|
ITCA 650 (exenatide, delivered continuously once or twice yearly through a matchstick-sized, subcutaneous osmotic mini-pump) |
type 2 diabetes |
3 |
Intarcia Therapeutics (USA - MA) |
Metabolic diseases |
2016-05-09
|
ConfirmMDx® for Prostate Cancer |
prostate cancer |
|
MDxHealth (Belgium) |
Cancer - Oncology - Diagnostic |
2016-05-09
|
ulipristal acetate |
uterine fibroids |
3 |
Gedeon Richter (Hungary) Allergan (Ireland) |
Gynecology - Women's health |
2016-05-06
|
ARC-LPA |
cardiovascular diseases |
preclinical |
Arrowhead Research Corporation (USA - CA) |
Cardiovascular diseases |
2016-05-06
|
ProSavin®/OXB-101 |
Parkinson's disease |
1-2 |
Oxford Biomedica (UK) |
Neurodegenerative diseases |
2016-05-05
|
glufosfamide |
metastatic pancreatic adenocarcinoma |
3 |
Eleison Pharmaceuticals (USA - FL) |
Cancer - Oncology |
2016-05-05
|
ozanimod (RPC1063) |
moderate to severe ulcerative colitis |
2 |
Celgene (USA - NJ) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-05-04
|
elsiglutide (ZP1846) |
prevention of chemotherapy-induced diarrhea in cancer patients |
2b |
Zealand Pharma (Denmark) Helsinn (Switzerland) |
Cancer - Oncology |
2016-05-04
|
VXM01 |
patients with metastatic colorectal cancer whose disease has progressed following one or two prior therapies |
2a |
Vaximm (Germany) |
Cancer - Oncology |
2016-05-04
|
ISTH0036 - antisense oligonucleotide directed against TGF-ß2 mRNA |
patients with advanced glaucoma undergoing filtration surgery (trabeculectomy) due to uncontrollable elevated intraocular pressure (IOP) |
1 |
Isarna Therapeutics (Germany) |
Ophtalmological diseases |
2016-05-04
|
tildrakizumab (MK-3222) |
psoriasis |
3 |
Merck&Co (USA - NJ) Sun Pharmaceutical Industries (India) |
Autoimmune diseases - Dermatological diseases - Inflammatory diseases |
2016-05-03
|
citarinostat (ACY-241), ipilimumab and nivolumab |
melanoma |
1b |
Acetylon Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2016-05-03
|
ALX-0171 |
Respiratory Syncytial Virus (RSV) infection |
1-2a |
Ablynx (Belgium) |
Infectious diseases - Respiratory diseases |
2016-05-02
|
Grafix® |
acute and chronic wounds |
|
Osiris Therapeutics (USA - MD) |
|
2016-05-02
|
CGF166 |
severe-to-profound bilateral hearing loss with intact vestibular function in the non-operative ear |
1-2 |
Novartis (Switzerland) Genec (USA - MD) |
Otorhinolaryngology |
2016-05-02
|
fasinumab |
moderate-to-severe osteoarthritis pain of the hip or knee |
2-3 |
Regeneron Pharmaceuticals (USA - NY) |
Rheumatic diseases - Inflammatory diseases |
2016-05-02
|
sacituzumab govitecan - IMMU-132 |
advanced, metastatic solid cancers |
2 |
Immunomedics (USA - NJ) |
Cancer - Oncology |
2016-05-02
|
TB-403 |
relapsed or refractory medulloblastoma |
1-2a |
BioInvent (Sweden) Thrombogenics (Belgium) Oncurious (Belgium) Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) (USA - MI) |
Cancer - Oncology |
2016-04-29
|
galinpepimut-S (human Wilms tumor protein 1 peptides - WT1 vaccine) and nivolumab (Opdivo®) |
ovarian cancer |
1 |
SELLAS Life Sciences (Switzerland) |
Cancer - Oncology |
2016-04-28
|
fluorescent analog of RXI-109 |
|
preclinical |
RXi Pharmaceuticals (USA - MA) |
Ophtalmological diseases - Dermatological diseases |